Skip to main content

Hematologic Adverse Reactions

HEMATOLOGIC ADVERSE REACTIONS¹

(Integrated Safety Dataset of ES-SCLC Patients From Across the 3 Studies)^a

Summary is based on the integrated safety dataset from across the three studies¹
Patients included are those randomized patients who received at least 1 dose of COSELA (n=122) or placebo (n=118)¹
Data reflect adverse reactions observed by investigators at any time during the treatment period

ES-SCLC=extensive-stage small cell lung cancer.

^aResults were not statistically compared.

< Previous PRO: Pooled Data
Learn more >

Hear how one of your peers incorporated COSELA into their practice